Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Continue Providing Emerging Safety Info, But Not Through Drug Watch

Executive Summary

Despite FDA's decision to drop its proposed "Drug Watch" Web site, the agency will continue to make emerging drug safety information available to the public

You may also be interested in...



Drug Safety Communications Are Not Crisis Management Tools, FDA Says

A new draft guidance explains the Center for Drug Evaluation and Research’s approach to communicating emerging drug safety information. Since 2010, Drug Safety Communications have replaced a variety of audience-focused tools laid out in a 2007 guidance, but FDA says public health alerts will be used to communicate about products that pose an immediate danger.

Should FDA Drug Safety Alerts Go To Professionals First?

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24

Should FDA Drug Safety Alerts Go To Professionals First?

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel